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Abstract
Background: Homeopathic medicine is a branch of integrative medicine that has been gaining increasing
popularity. However, its clinical application remains controversial.
To improve the understanding of homeopathy, observational studies-which monitor the effects of homeopathy in
real-life clinical settings-are a helpful adjunct to randomized controlled trials.
The goal of this controlled observational study was to investigate the role of the homeopathic medicine in
preventing respiratory tract infections (RTIs).
Methods: This retrospective analysis of patients’ medical records focused on a single centre from 2002 to 2011, and
examined 459 patients, out of whom 248 were treated with homeopathic medicine (specific extract of duck liver
and heart) and 211 were not treated. All patients were followed-up for at least 1 year, and up to a maximum of
10 years.
Results: A significant reduction in the frequency of onset of RTIs was found in both the homeopathic medicine
and untreated groups. The reduction in the mean number of RTI episodes during the period of observation vs. the
year before inclusion in the study was significantly greater in the homeopathic-treated group than in untreated
patients (-4.76 ± 1.45 vs. -3.36 ± 1.30; p = 0.001). The beneficial effect of the homeopathic medicine was not
significantly related to gender, age, smoking habits or concomitant respiratory diseases when compared to the
effect observed in untreated patients.
Conclusion: These results suggest that homeopathic medicine may have a positive effect in preventing RTIs.
However, randomized studies are needed before any firm conclusion can be reached.
Keywords: Comparative study, Integrative therapies, Homeopathy, Observational study, Oscillococcinum,
Respiratory tract infections
Background
Integrative medicine (IM) refers to all those treatments
that are not part of conventional healthcare. Homeop-
athy is a system of IM that was developed in Europe at
the end of the eighteenth century employing medicines
prepared according to a well-defined procedure starting
from mineral, herbal or animal substances. The tech-
niques for preparing these medicines include the re-
peated dilution of the raw material in hydro-alcoholic
solutions or in other excipients, and the ‘succussion’ of
the product into different grades [1, 2].
Despite its controversial nature, clinical use of hom-
eopathy has risen steadily in recent years, encouraged by
the fact that some of its mechanisms of action have been
elucidated and described in randomized controlled trials,
meta-analyses or systematic reviews [3–8]. However,
other authors have instead negatively evaluated the effi-
cacy of homeopathic medicines, suggesting that they do
not yield clinical effects different from placebo [9, 10].
According to the 2012 National Health Interview Sur-
vey (NHIS) approximately 5 million adults and 1 million
children in the United States used homeopathy in 2011
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[11]. According to the 2014 Italian National Institute of
Statistics (ISTAT) survey, homeopathic products have
been used by approximately 2.5 million people in Italy in
the years 2010–2013 and they have been prescribed by
over 20,000 physicians [12].
Another debated point in homeopathy is its lack of pre-
scribing standards, as a result of which treatments can be
highly individualised for a broad variety of symptoms.
To address these uncertainties, some recent studies have
investigated homeopathic treatment protocols using large
cohorts of patients and long follow-up periods, so as to
monitor the real-world effectiveness of homeopathic
medicine in everyday clinical practice [13].
An observational longitudinal study conducted in Italy
between 1998 and 2008 analysed the socio-demographic
features and the outcomes of a paediatric population
treated with homeopathic medicine. The results were
promising and indicated a positive therapeutic response,
especially in children affected by respiratory diseases [14].
A specific extract of duck liver and heart has been au-
thorized since 1944 and is sold in over 80 countries
around the world. It is used for the prevention and treat-
ment of influenza and of viruses that cause influenza-like
syndromes. A patented preparation of this homeopathic
medicine is commercially available as a Korsakovian dilu-
tion (200 K) manufactured from wild duck heart and liver.
One dose of this patented preparation contains Anas Bar-
bariae, hepatis and Cordis extractum, as well as the su-
crose and lactose as excipients. The ultra-molecular
dilutions of this remedy have raised some concerns about
its effectiveness, but recently published evidence from in
vitro biological models has shown that this kind of
homeopathic dilution can elicit significant physiological
effects [15, 16]. Thanks to its composition, which may be
a reservoir of infective agents responsible of respiratory
tract infections (RTIs), this homeopathic medicine is regu-
larly used by many people over the winter months for
seasonal colds and airway inflammatory affections [17]. It
is well known that RTIs-which comprise any infection of
the sinuses, throat, airways or lungs-usually present a viral
aetiology. However, RTIs can also be caused by bacteria,
and are among the top two causes of morbidity and mor-
tality worldwide [18].
Existing treatment strategies for influenza-like syn-
dromes and RTIs have been shown to have a limited ef-
fect on symptoms, also due to the spread of antibiotic
and antiviral resistance cases [18, 19]. The aims of those
treatments were to enhance the general health of pa-
tients by improving symptom control and reducing the
frequency of RTI episodes.
This paper presents the results of a retrospective con-
trolled observational study designed to examine health
changes, expressed as the reduction in the average num-
ber of RTI episodes per year, of a cohort of patients
undergoing homeopathic treatment versus a control
group of untreated patients, in a real-world setting.
Methods
Patients
Between January 1st 2002 and December 31st 2011, overall
outcomes were recorded for 459 consecutive patients with
RTI or respiratory recurrent infection (IRR) (221 males,
48.1 %; 238 females, 51.9 %. Age range: 1–84 years; mean
± SD: 30.9 ± 25.2 years; IQR: 6–50 years) who were re-
ferred to a respiratory diseases specialist office in Agna-
dello (Cremona, Italy). Inclusion criteria were: all patients
included in the study had at least three episodes of RTIs
in the year preceding the start of treatment or observation,
and at least one year of follow-up after the start of treat-
ment/observation We studied patients with RTI episodes
of both upper or lower airways and the presence of a RTI
episode was considered when patients presented any ear,
throat, airways or lungs infections, as well as sore throat,
tonsillitis, laryngitis, sinusitis, stiffy or runny nose, cough,
common cold, etc. Subjects who had taken any form of flu
vaccine or any other type of vaccine (immunostimulants,
bacterial lysates, or similar) were excluded from the obser-
vational study. Patients with psychiatric disorders and/or
inability to follow the prescriptions were also excluded.
Ethics
This study was notified to the regional Independent
Ethical Committee of Lombardy region. According to
the Italian regulation (“Guidelines for the classification
of observational study of drug”; May 20th, 2008) no ap-
proval of the Committee is needed for observational
studies. All the subjects gave their written informed
consent for the use of their data in this study. The
study protocol conforms to the ethical guidelines of
the “World Medical Association (WMA) Declaration
of Helsinki-Ethical Principles for Medical Research In-
volving Human Subjects” adopted by the 18th WMA
General Assembly, Helsinki, Finland, June 1964.
First visit (enrollment)
At the first consultation, the current state of health and
the nature of each patient’s symptoms were evaluated and
recorded in detail. The presence of an RTI was diagnosed
by a physical examination, and was defined as comprising
one or more of the following complaints: acute inflamma-
tion of the throat, red pharyngeal mucosa, ear pain, acute
otitis media, streptococcal infection, sinusitis or tonsillitis,
inflammation of the larynx. Objective parameters were
incorporated into the records whenever possible, to-
gether with the patient’s demographic details and clin-
ical diagnosis. For patients with a known pre-existing
disease, such as chronic obstructive pulmonary disease
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(COPD) or bronchial asthma, standard tests (e.g.,
pulmonary function tests, etc.) were requested.
Treatment
Out of the 459 enrolled patients, 248 subjects (54.0 %)
were treated with a homeopathic medicine (a specific
extract of duck liver and heart; Oscillococcinum®, Boiron
SA, Messimy, France), while 211 patients (46.0 %) were not
treated (control group). The physician initially instructed
all 459 patients to take 1 dose of homeopathic medicine
(contains 1 g about 200 pillules impregnated with 0.01 mL
of the specific extract of duck liver and heart) a week for
8 months (from early September to late April), and to
repeat the treatment during the subsequent years. The pa-
tients purchased the treatment and took it on their own
account. The administration of any kind of vaccine was
avoided during the study period for patient choice inde-
pendently from the medical recommendation.
Adherence to the treatment was evaluated by the med-
ical doctor during subsequent consultation visits and/or
by telephone contact. A total of 211 patients were found
to be non-compliant (i.e., they did not take the homeo-
pathic medicine as recommended by the medical doc-
tor), and these formed the control group.
The characteristics of the two groups of patients are
shown in Table 1. The most represented province in the
Table 1 Characteristics of the enrolled patients in the treated (specific extract of duck liver and heart) and untreated groups




(n = 459) (n = 248) (n = 211)
Province of residence: 0.553b
- Cremona 261 (56.9 %) 140 (56.5 %) 121 (57.2 %)
- Bergamo 91 (19.8 %) 48 (19.4 %) 43 (20.4 %)
- Milan 86 (18.7 %) 51 (20.6 %) 35 (16.6 %)
- Others 21 (4.6 %) 9 (3.6 %) 12 (5.7 %)
Gender: 0.574c
- Male 221 (48.1 %) 116 (46.8 %) 105 (49.8 %)
- Female 238 (51.9 %) 132 (53.2 %) 106 (50.2 %)
Age classes: 0.032b
- 1-2 years 29 (6.3 %) 19 (7.7 %) 10 (4.7 %)
- 3-5 years 74 (16.1 %) 48 (19.4 %) 26 (12.3 %)
- 6-17 years 90 (19.6 %) 54 (21.8 %) 36 (17.1 %)
- 18-64 years 201 (43.8 %) 96 (38.7 %) 105 (49.8 %)
- 65 or more years 65 (14.2 %) 31 (12.5 %) 34 (16.1 %)
Smoking habits: 0.703b
- No smokers 282 (61.4 %) 155 (62.5 %) 127 (60.2 %)
- Passive smokers 42 (9.2 %) 25 (10.1 %) 17 (8.1 %)
- Former smokers 62 (13.5 %) 32 (12.9 %) 30 (14.2 %)
- Current smokers 73 (15.9 %) 36 (14.5 %) 37 (17.5 %)
No. of concomitant respiratory diseases: 0.168d
- None 171 (37.3 %) 86 (34.7 %) 85 (40.3 %)
- 1 disease 184 (40.1 %) 101 (40.7 %) 83 (39.3 %)
- 2 diseases 104 (22.7 %) 61 (24.6 %) 43 (20.4 %)
Concomitant respiratory diseases:
- COPDa 63 (13.7 %) 33 (13.3 %) 30 (14.2 %) 0.787c
- Respiratory allergy 195 (42.5 %) 109 (44.0 %) 86 (40.8 %) 0.508c
- Asthma 105 (22.9 %) 55 (22.2 %) 50 (23.7 %) 0.739c
- Other respiratory diseases 29 (6.3 %) 26 (10.5 %) 3 (1.4 %) <0.001c
a COPD: chronic obstructive pulmonary disease
b Pearson chi-square test
c Fisher’s exact test
d Linear-by-linear chi-square test
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cohort was Cremona (n = 261, 56.9 %), with no signifi-
cant difference between the treated and untreated group
(p = 0.553). The distribution of patients according to
gender was similar in the two groups (p = 0.574) but the
patients in the treated group were significantly younger
than the patients in the untreated group at the time of
inclusion in the study (p = 0.032). In fact, the most popu-
lated age class was 18–64 years in both groups (n = 96,
38.7 and n = 105, 49.8 % for the treated and untreated
group, respectively) while a total of 67 patients (27.0 %)
in the homeopathic medicine group were less than six
years old against just 36 such patients in the untreated
group (17.1 %), and patients older than 64 were fewer in
the treated (n = 31, 12.5 %) than in the untreated (n = 34,
16.1 %) group.
One hundred and seventy-seven patients (38.6 %) were
smokers (passive, former, or current smokers) and a close
relationship was found between smoking habits and both
gender (p = 0.001) and age (p < 0.001). In particular,
former smokers were more frequently male than female
(n = 44, 19.9 vs. n = 18, 7.6 %) while current smokers were
more frequently female (n = 46, 19.3 vs. n = 27, 12.2 %). As
far as smoking habits and age were concerned, it should
be pointed out that not all patients aged under 18 were
non smokers; in fact, there were 3 (10.3), 10 (13.5) and 9
(10.0 %) patients who were passive smokers within the
1–2 year, 3–5 year and 6–17 year age ranges respectively,
while one only patient (1.1 %) was a current smoker in the
6–17 year age range. Patients aged 18–64 were mostly
nonsmokers (n = 99, 49.3 %) while patients over 64 years
old were mostly former smokers (n = 37, 56.9 %). On the
other hand, no significant difference in smoking habits
were found between the treated and untreated groups
(p = 0.703).
A total of 288 patients (62.7 %) had concomitant re-
spiratory diseases. Out of these, 184 (40.1 %) patients had
one concomitant respiratory disease and 104 (22.7 %) had
two concomitant diseases, so that a total of 392 concomi-
tant respiratory diseases were recorded. Both the number
of concomitant respiratory diseases (p = 0.168) and the
frequencies of chronic obstructive pulmonary disease
(COPD), allergies and asthma were not significantly dif-
ferent between the two groups (p = 0.787, p = 0.508, and
p = 0.739, respectively), but the frequency of other re-
spiratory diseases, although affecting only a small mi-
nority of patients (6.3 %), was significantly higher in the
homeopathic-treated group (n = 26, 10.5 vs. n = 3, 1.4 %;
p < 0.001). COPD was significantly more frequent in males
than in females (n = 43, 19.5 vs. n = 20, 8.4 %; p = 0.001),
while no significant differences between males and females
were found for allergies, asthma and the other respiratory
diseases (p = 1.000, p = 0.150, and p = 0.565, respectively).
The presence of COPD, allergies and asthma was signifi-
cantly (p ≤ 0.001) related to age and smoking habits. In
particular, COPD was highly frequent among the oldest pa-
tients (over 64 years old: n = 49, 75.4 %) as well as among
former smokers (n = 42, 67.7 %) and current smokers
(n = 17, 23.3 %); allergies were more frequently reported
by patients aged 6-17 and 18–64 years (n = 56, 62.2 and n
= 99, 49.3 %, respectively) and by passive (n = 23, 54.8 %)
and nonsmokers (n = 132, 46.8 %); finally, asthmatic pa-
tients were more frequently present in 18–64 year age span
(n = 64, 31.8 %) and in passive smokers (n = 18, 42.9 %).
The presence of other concomitant respiratory diseases was
not significantly related to age (p = 0.496) or to smoking
habits (p = 0.679).
Follow-up
At each subsequent yearly consultation, the patient’s state
of health was evaluated and a data form was completed
containing the patient’s clinical details and diagnosis. The
duration of the observation period varied between 1 and
10 years with a mean ± SD value of 5.3 ± 2.6 years (IQR: 3–
7 years). In general, 46 (10.0 %) patients were followed up
for 1 year, 150 (32.7 %) for 2–4 years and 263 (57.3 %) for
5 or more years. A total of 21 (4.6 %) patients ended the
follow-up before 2012: out of these, 8 (3.2 %) were in the
active treatment group and 13 (6.2 %) in the untreated
group (p = 0.178). The follow-up period was slightly lon-
ger for the homeopathic medicine group (5 years or
more: n = 153, 61.7 vs. n = 110, 52.1 %; 2–4 years: n =
73, 29.4 vs. n = 77, 36.5 %; 1 year: n = 22, 8.9 vs. n = 24,
11.4 %; homeopathic-treated vs. untreated patients) but
the difference did not reach the significance threshold
(p = 0.055).
Outcome measures
The primary outcome measure for assessing the effect-
iveness of the preventive treatment with homeopathic
medicine was the reduction in the average number of
RTI episodes per year versus the year before inclusion
in the study.
A secondary outcome was the evaluation of the pos-
sible effects of other variables (gender, age, smoking
habits and concomitant respiratory diseases) on the re-
duction in the average number of RTI episodes.
Annual numbers of episodes of RTI before inclusion in
the study
The mean (±SD) number of episodes of RTI before of
inclusion in the study was 5.01 ± 1.66 (range: 3–18; IQR:
4–5). Patients in the group treated with the homeopathic
medicine had a significantly higher number of episodes
than the untreated group, (5.42 ± 1.69 versus 4.53 ± 1.49;
p = 0.004). In particular, the majority of patients (n =
263, 57.3 %) had at least five episodes of RTI in the year
before inclusion in the study: out of these, 184 patients
(74.2 %) were in the treated group and 79 (37.4 %) in the
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untreated group (p < 0.001). This finding is in line with
the observational type of experimental protocol, since
patients were not randomly assigned to one of the two
treatment groups, and it reflects everyday clinical med-
ical practice, providing a photograph of how the medi-
cine is actually used.
Gender (p = 0.999), smoking habits (p = 0.899), and
presence of concomitant respiratory diseases (p = 0.658,
p = 0.901, p = 0.695, and p = 0.830 for COPD, respiratory
allergy, asthma and other respiratory diseases, respect-
ively) were not significantly associated with the number
of episodes of RTI suffered by patients in the year before
the start of the study. Conversely, the number of episodes
of RTI before inclusion in the study was inversely related
to the age of patients (p = 0.001). In particular, children
aged 1–2 and 3–5 years had a significantly greater number
of episodes (6.03 ± 2.06, p = 0.015; 6.41 ± 2.75, p < 0.001
respectively) than adult patients (4.45 ± 0.88 episodes in
patients aged 18–64 years), while no significant differences
were found between both patients aged 6–17 years (4.94
± 1.32, p = 0.206) and older patients (more than 64 years:
4.80 ± 0.85, p = 0.693) when compared to adults.
Statistical analysis
The descriptive analysis of scalar variables was per-
formed using the mean and the standard deviation (SD),
as well as the overall and the interquartile (IQR) ranges,
whereas categorical variables were described by the ab-
solute and relative frequencies. Fisher’s exact, Pearson’s
chi-squared and the linear-by-linear chi-squared tests
were used to analyze dichotomous, nominal and ordinal
discrete variables respectively, while the general linear
models were applied to analyze scalar variables. The z-test
was used for checking the skewness of scalar variables:
number of RTI episodes reported at each year of follow-
up, as well as the mean number of RTI episodes during
the follow-up, displayed highly significant positive skew-
ness coefficients (p < 0.001) and were transformed before
analysis according to the formula log (x + k). On the other
hand, the primary outcome measure (i.e., the difference in
the average number of RTI episodes per year versus the
year before inclusion in the study) showed a highly
significant negative skewness (p < 0.001), and was ac-
cordingly transformed by the exp (x / k) formula. The
values of the constant coefficients (k) that maximized
the Shapiro-Wilk’s statistics for the normal distribu-
tion of each scale variable were chosen in the trans-
formation functions.
The average number of RTI episodes per year and its dif-
ference versus the values observed before the study (i.e., the
primary endpoint) were assessed by means of eight-way
analyses of variance (ANOVA), making adjustments for all
eight factors considered in this study (i.e., treatment group,
gender, age, smoking habits, and the four concomitant
respiratory diseases). Nine-way ANOVA was instead ap-
plied to analyse the number of RTI episodes, because the
year of follow-up was also considered as an adjusting factor
in that analysis. The interactions between treatment group
and the other factors were also included in the model to
test whether the differences observed between treated and
untreated patients differed significantly depending on the
classes of the various factors taken into account. To avoid
multiple comparisons, simple contrast was used to
compare pairs of classes of non-dichotomous discrete
variables, while repeated contrast was used to test pro-
gressive changes in the number of RTI episodes at each
year of follow-up compared to the preceding year. In
addition, nested designs were used to test differences
between the treatment groups within each class of the
various factors, as well as to compare the different clas-
ses of the various factors within each treatment group.
Data were managed and analyzed using the IBM SPSS
Statistics package (Version 21, IBM, Co., Armonk, NY,
USA) and statistical significance was considered to be
achieved for two-tailed p values lower than 0.05.
Results
RTI episodes during the study
Four thousand and ten episodes of RTI were recorded
during the 10–year study period, with a mean number of
yearly episodes of 1.40 ± 1.89 (range: 0–18; IQR: 0–2). In
particular 44 (9.6 %) patients had no RTI episodes dur-
ing the follow-up: 42 (16.9 %) in the group taking the
specific extract of duck liver and heart and 2 (0.9 %) in
the untreated group (p < 0.001). The distribution of the
average number of episodes of RTI in the 10 years of
follow-up is shown in Fig. 1. A significant reduction (p <
0.001) in the number of RTI episodes compared to those
observed before treatment was found in both groups over
the course of the full 10 years of follow-up, showing a pro-
gressive decrease of RTI episodes in both groups. In fact,
the difference between the number of RTI episode ob-
served at each time compared to the number of RTI epi-
sodes observed in the preceding year reached significance
from the 1st to the 3rd year for both groups, although the
reduction between the 1st and 2nd year did not reach sig-
nificance in the homeopathic medicine group (p = 0.106).
The comparison between the two groups showed that,
although the treated group had a significantly higher
number of RTI episodes in the year before the study
(p = 0.004), in the first 9 years of follow-up the num-
ber of RTI episodes was significantly lower in patients
treated with the homeopathic medicine than in the
untreated patients while it did not reach significance
only in the last year (p = 0.262).
The mean number of RTI episodes per year reported
by the 459 patients ranged from 0 to 5 with a mean
value of 0.90 ± 0.82 (IQR: 0.33–1.20). The treated group
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had a significantly (p < 0.001) lower mean number of
RTI episodes per year (0.67 ± 0.67) than patients in the
untreated group (1.17 ± 0.89).
Primary outcome measure: reduction in the number of
RTI episodes during follow-up
The change in the mean number of episodes of RTI dur-
ing the follow-up versus the pre-treatment value ranged
from -16.0 to -1.00 (mean ± SD: -4.11 ± 1.55; IQR: -4.83
to -3.30) and was significantly greater (p = 0.001) in the
treated patients (-4.76 ± 1.45) than in untreated patients
(-3.36 ± 1.30).
Reduction in the number of RTI episodes according to gender
The reduction in the number of episodes of RTI per year
during the follow-up period versus the number of episodes
of RTI before inclusion in the study was not significantly
related to gender in the overall population (p = 0.688), nor
within the two groups of patients (homeopathic medicine
group: p = 0.643; untreated group: p = 0.342). This reduc-
tion was significantly greater in patients belonging to the
treated group when compared to untreated patients of
both sexes (males: -4.82 ± 1.31 vs. -3.38 ± 1.67, p < 0.001;
females: -4.70 ± 1.57 vs. -3.33 ± 0.76, p = 0.002), thus in-
dicating that the positive effect of the specific extract of
duck liver and heart is similar for both males and females
(p = 0.309 interaction between gender and treatment).
Reduction in the number of RTI episodes according to age
Compared to patients of the untreated group in the
same age class, patients in the homeopathic medicine-
treated group had a significantly greater reduction in the
mean number of RTI episodes per year during the study,
as shown in Table 2 (p ≤ 0.020). The reduction in the
number of RTI episodes differed significantly among age
classes in the general population (p = 0.010); this was
due to the differences in reduction of the number of RTI
episodes among age classes in the homeopathic medi-
cine group (p = 0.048), whereas no significant differences
among age classes were found in the untreated patients
(p = 0.191). In particular, the effect of the specific extract
of duck liver and heart was significantly higher in chil-
dren aged 3–5 years (p = 0.010) than in the adult popula-
tion (18–64 years). It should be pointed out that the
reduction of RTI episodes in both the youngest (1–2 years)
and oldest (more than 64 years) patients was similar to
the reduction observed in adults (18–64 years). Finally,
the comparison of the reductions in RTI episodes ob-
served in homeopathic-treated versus untreated pa-
tients was not significantly related to age (p = 0.754;
interaction between age and treatment).
Reduction in the number of RTI episodes according to
smoking habits
Similarly to the above findings for gender and age, the
homeopathic medicine group showed a significantly
greater reduction in the number of RTI episodes com-
pared to untreated patients also within all subgroups
of patients with different smoking habits (p ≤ 0.011)
(Table 3). No significant differences among different
smoking classes were found in the overall population
(p = 0.899), nor within the two groups of treatment
(treated group: p = 0.684; untreated group: p = 0.895),
and no significant interaction was found between gen-
der and treatment (p = 0.685).
Fig. 1 Behaviour of yearly number of RTI episodes before and during the 10-year follow-up in the treated (specific extract of duck liver and heart)
and untreated groups. Data are reported as mean ± SD values. The p values of the comparison between the two groups are shown in the figure.
ap < 0.001, bp = 0.002, cp = 0.006: comparison vs. the previous year within each treatment group
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Reduction in the number of RTI episodes depending on
concomitant respiratory diseases
As shown in Table 4, the difference between the mean
number of RTI episodes per year during the period of pre-
ventive treatment and the mean number of episodes of RTI
per year before the inclusion in the study was significantly
greater for patients belonging to the homeopathic medicine
group than for patients in the untreated group, irrespective
of whether they had any of the four types of respiratory dis-
eases (p ≤ 0.033). No significant differences of the change in
the mean number of RTI episodes per year were found
between patients with and without concomitant dis-
eases, both within the general population (p ≥ 0.187)
and within the two groups of patients (treated group:
p ≥ 0.152; untreated group: p ≥ 0.051). Similarly, the in-
creased reduction observed in the homeopathic medicine
group as compared to untreated patients was also unrelated
to the presence of any of the four concomitant respiratory
diseases (interactions: p = 0.380, p = 0.120, p = 0.051, and
p = 0.384 for COPD, allergies, asthma and other diseases,
respectively).
Discussion
The main focus of this retrospective observational study
was to explore the effect of the specific extract of duck
liver and heart in the prevention of RTIs, by comparing
two groups of patients, one that took the medicine and
the other that did not.
Table 2 Difference between the mean number of RTI episodes per year during the follow-up period and the number of episodes of
RTI before inclusion in the study stratified according to age classes in the treated (specific extract of duck liver and heart) and
untreated groups




(n = 459) (n = 248) (n = 211)
1–2 years -4.22 ± 2.03 -4.77 ± 2.13 -3.17 ± 1.35 0.020
p = 0.361 p = 0.746 p = 0.366
3–5 years -5.01 ± 2.57 -5.47 ± 2.15 -4.16 ± 3.07 0.007
p = 0.005 p = 0.010 p = 0.138
6–17 years -4.32 ± 1.30 -4.98 ± 1.24 -3.33 ± 0.54 0.003
p = 0.083 p = 0.063 p = 0.526
18–64 years -3.83 ± 0.96 -4.44 ± 0.83 -3.28 ± 0.69 0.005
Reference Reference Reference
65 years and over -3.63 ± 1.04 -4.24 ± 0.96 -3.07 ± 0.76 <0.001
p = 0.431 p = 0.775 p = 0.191
Overall p value among age classes p = 0.010 p = 0.048 p = 0.191 -
The effects observed in the various age classes are also compared with those observed in the adult population (18-64 years)
Table 3 Difference between the mean number of RTI episodes per year during the follow-up period and the number of episodes of
RTI before inclusion in the study stratified according to smoking habits in the treated (specific extract of duck liver and heart) and
untreated groups




(n = 459) (n = 248) (n = 211)
Nonsmokers -4.25 ± 1.75 -4.92 ± 1.63 -3.43 ± 1.54 0.001
Reference Reference Reference
Secondhand smokers -4.16 ± 1.36 -4.69 ± 1.31 -3.38 ± 1.06 0.010
p = 0.749 p = 0.645 p = 0.973
Former smokers -3.72 ± 0.99 -4.21 ± 0.91 -3.20 ± 0.79 0.011
p = 0.680 p = 0.920 p = 0.492
Current smokers -3.90 ± 1.05 -4.59 ± 0.90 -3.23 ± 0.69 <0.001
p = 0.544 p = 0.365 p = 0.936
Overall p value among smoking habit classes p = 0.899 p = 0.684 p = 0.895 -
The effects observed in the various smoking classes are also compared with those observed in nonsmokers
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The results indicate that the evaluated homeopathic
drug has a preventive effect on the onset of RTI episodes.
Although the role of this drug has been vividly debated,
the protective effect observed here is consistent with other
studies that have documented its effect on the treatment
of flu and flu-like symptoms [9, 20–22]. Thus, our findings
add to the growing body of knowledge that could ultim-
ately indicate this homeopathic medicine as a beneficial
preventive treatment of RTIs [6].
Moreover, observational data from real-life homeopathic
practice are becoming increasingly useful to evaluate the
role of this type of IM in treating a wide range of chronic
and acute diseases. These results should not be underesti-
mated, also because any gain in health offered by homeo-
pathic medicine, alone or in combination with standard
medicine, could be considered of value to the healthcare
system in managing the yearly seasonal epidemics that
cause RTIs each winter.
An analysis of recent data (2014) of winter all-cause
mortality collected by 14 EU countries showed excess
mortality levels higher than those seen in the past three
winters, especially among older people; these deaths
were likely related to RTI [23].
With respect to the analysis of the cohort baseline
characteristics, our results indicate that the patients in-
cluded in the treated group were younger and had more
episodes of RTIs during the year before inclusion in the
study compared to subjects in the untreated group,
whereas the province of residence, gender, smoking
habits and distribution of respiratory pathologies were
similar for the two groups.
During the observation period, patients treated with the
homeopathic medicine had a lower number of respiratory
tract infection episodes than untreated patients. In particu-
lar, we found that untreated patients who had a mean of
4–5 episodes of exacerbation the year before the study
maintained a mean of 2 or less episodes of exacerbation
during a subsequent 10-year follow-up without any pre-
ventive treatment. It should be pointed out that the values
of 4–5 episodes of exacerbation were observed when the
patients did not attend the medical consulting while during
the study the observed patients had various concomitant
pathologies and concomitant pharmacological treatments
which were adjusted by the practitioner - for each individ-
ual clinical case of both groups - as a function of the
patient’s short and long-term medical history. Thus the
reduction in the number of infections also among patients
in the control group can be accounted for by various fac-
tors such as the optimisation of the background therapy.
In fact, often, allergic subjects were not following any kind
of therapy or asthmatics were not following a bronchodila-
tor background therapy before entering in the study.
The reduction in the mean number of RTI episodes
during the observation period versus the mean number
Table 4 Difference between the mean number of RTI episodes per year during the follow-up period and the number of episodes of
RTI before inclusion in the study stratified according to the presence of concomitant respiratory diseases in the treated (specific
extract of duck liver and heart) and untreated groups
Concomitant respiratory
diseases




(n = 459) (n = 248) (n = 211)
COPDa
- No -4.19 ± 1.60 -4.85 ± 1.49 -3.40 ± 1.36 p < 0.001
- Yes -3.66 ± 1.00 -4.16 ± 0.93 -3.11 ± 0.77 p = 0.033
p = 0.330 p = 0.152 p = 0.949
Respiratory allergy:
- No -4.10 ± 1.63 -4.75 ± 1.63 -3.38 ± 1.29 p = 0.003
- Yes -4.13 ± 1.43 -4.76 ± 1.19 -3.33 ± 1.31 p < 0.001
p = 0.187 p = 0.860 p = 0.051
Asthma:
- No -4.15 ± 1.60 -4.84 ± 1.56 -3.32 ± 1.22 p < 0.001
- Yes -4.00 ± 1.33 -4.47 ± 0.92 -3.84 ± 1.52 p = 0.013
p = 0.909 p = 0.182 p = 0.154
Other respiratory diseases:
- No -4.07 ± 1.45 -4.73 ± 1.26 -3.36 ± 1.30 p < 0.001
- Yes -4.77 ± 2.52 -4.98 ± 2.57 -2.96 ± 0.86 p = 0.015
p = 0.394 p = 0.980 p = 0.360
aCOPD chronic obstructive pulmonary disease
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of RTI episodes in the year before inclusion in the study
was statistically higher in the group of patients treated
with the homeopathic medicine than in the untreated
group. Both these observations indicate a possible pre-
ventive effect of the homeopathic medicine on the onset
and development of RTIs.
Importantly, the greater reduction in RTI episodes for
the treated group during the overall treatment, compared
to patients belonging to the untreated group, was evident
irrespective of gender, smoking habits, or the profile of
concomitant respiratory diseases. However, the situation
for age class distribution was different. Patients treated
with specific extract of duck liver and heart did have a
greater reduction in the average infectious episodes during
the study compared to the year before inclusion than did
patients of the untreated group, independently of what
age class they belonged to. However, age may have never-
theless played a role in reducing RTI episodes among the
treated patients, since the reduction in episodes among
these patients seemed greater for patients less than
18 years old (particularly in the 3-5 year age class). This
observation is consistent with the pathophysiology of RTIs
which are much more prevalent in paediatric/adolescent
age than in adults. The exact mechanisms responsible for
these observed effects are not clear yet. The literature sug-
gests that ultra-molecular homeopathic dilutions (such as
specific extract of duck liver and heart) may exert their
effects through a peculiar water structure. However, more
evidence of this is needed [24, 25].
This study has several limitations. One particular issue is
its observational design which, as documented elsewhere
[26], is susceptible to inherent biases associated with the
collection of non-random data. In addition, the use of an
untreated control group, rather than a placebo-treated
one, might be questionable. In this connection, it should
be noted that a Cochrane meta-analysis on this same
medicine [27] could not give a robust conclusion on the
effectiveness of Oscillococcinum owing to the quality of
the analysed studies; however, from the report it emerged
that those studies had found this homeopathic medicine to
have a therapeutic effect for the treatment of influenza-
like illness that was different from placebo. The present
study shows a snapshot of the use and therapeutic poten-
tial of this homeopathic medicine in a real-world, and the
results we have found need to be confirmed by large
randomized controlled studies. As regards the prevent-
ive effect of this medicine, the cumulative result of the
meta-analysis was protective but did not reach the sta-
tistically significant limit (overall risk ratio (RR) = 0.48;
95 % CI = 0.17–1.34). It should be considered that only
two studies were available for the meta-analysis [28, 29],
and that in both the RR was found to be protective. In par-
ticular, the first study [28] reported a very low RR value of
0.15 (indicating 85 % reduction in the risk of getting sick)
although the statistically significant limit was not reached;
most likely, this can be attributed to the low number of
events (n = 50 patients in each group) which “enlarged”
the confidence limits. The RR was also protective in the
second study (which evaluated 110 Oscillococcinum-
treated and 117 placebo-treated patients) [29] and proved
statistically significant, although it was less noticeable than
the RR of the first study (RR = 0.62; thus a risk reduction
of 38 %). Conversely, the main strength of this study is that
it provides objective data on the effects of homeopathic
care for a frequent and self-limiting condition, for which
the use of antibiotics is often ineffective or even inadvis-
able [30], in a fairly large number of patients. While there
is still not enough robust evidence that homeopathic
medicine has an effect on RTIs (thus, further controlled,
randomized studies are needed), the potential benefits of
homeopathic care in reducing antibiotic consumption has
been noted [31, 32]. A nationwide French survey of 518
adults and children with upper respiratory tract infections
(URTIs) compared antibiotic and antipyretic/anti-inflam-
matory drug usage, URTI symptom resolution and occur-
rence of potentially-associated infections in patients in
care with practitioners having different levels of prescrib-
ing preferences (i.e., homeopathic, general or mixed prac-
tice). The results of this study indicated that patients
followed by homeopathic practitioners showed signifi-
cantly lower consumption of antibiotics and antipyretic/
anti-inflammatory drugs with respect to those treated by
general or mixed practice practitioners, but still had a
similar evolution in related symptoms [30].
Finally, it should be pointed out that the evaluation of
any medical intervention should take into account not
only therapeutic efficacy, but also other factors such as
adverse events, costs and compliance. In this observa-
tional study the patients treated with the preventive
homeopathic medicine reported no adverse reactions, and
none of these patients has ever shown and/or reported
discomfort in tolerating this homeopathic medicinal prod-
uct during the period of observation.
Conclusions
The efficacy of homeopathy is often called into question,
mainly owing to the lack of a robust body of evidence
[33]. The respiratory tract infections usually have a strong
impact on individual well-being, thus it is understandable
why the percentage of patients who use homeopathic
medicines worldwide is constantly rising, and patient
satisfaction with such remedies is usually high [34].
This study suggests that the treatment with this spe-
cific homeopathic medicine could be a valuable tool for
preventing respiratory tract infections especially in light
of the absence of adverse reactions emerged and consid-
ering the good evaluation of the relationship between
benefits and risks/costs. Although there are limitations
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for the conclusions that can be drawn from this observa-
tional study, it provides a snapshot of the informational
role this medicine can play in everyday clinical practice,
and further randomized controlled trials are needed be-
fore definitive conclusions can be reached.
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